Tekmira and Bristol-Myers Squibb Expand Collaboration to Include Broader Applications of LNP Technology
17 mai 2011 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 17, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Tekmira Provides Corporate Update and Announces First Quarter 2011 Results
10 mai 2011 16h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, B.C., May 10, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced its financial and...
Tekmira Conference Call and Webcast Advisory: First Quarter 2011 Operating Results and Corporate Update
04 mai 2011 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 4, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that it...
Tekmira and the National Cancer Institute Publish Promising Data Demonstrating the Anti-Tumor Activity of a Novel Cancer Target
21 avr. 2011 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, April 21, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced...
Tekmira Announces USPTO Issuance of Key Patents Covering LNP Manufacturing Process and Mitigation of siRNA Immune Stimulation
12 avr. 2011 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, April 12, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced...
Tekmira Comments on Answer and Counterclaim Filed by Alnylam Pharmaceuticals
07 avr. 2011 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, B.C., April 7, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, reports that Alnylam...
Tekmira and Collaborators Present Data at the American Association for Cancer Research (AACR) Meeting on Tekmira's Lead Oncology Product, TKM-PLK1, and an Oncology Product Candidate Targeting Kinase WEE1
04 avr. 2011 16h35 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, April 4, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Tekmira Provides Corporate Update and Reports 2010 Audited Results
30 mars 2011 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 30, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced...
Tekmira Conference Call and Webcast Advisory: Corporate Update and 2010 Audited Results
28 mars 2011 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 28, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Tekmira Sues Alnylam Pharmaceuticals for Repeated Misuse of Trade Secrets and Confidential Information
16 mars 2011 16h40 HE
|
Arbutus Biopharma Corporation
Complaint Also Alleges Unfair and Deceptive Trade Practices, Unjust Enrichment, Unfair Competition and False Advertising about Tekmira's Proprietary Lipid Nanoparticle (LNP) Technology
Conference...